KTX-1029

KTX-1029 is a novel, potent, and highly selective small molecule inhibitor of MMSET/NSD2 (nuclear receptor binding SET domain protein 2), a histone lysine N-methyltransferase implicated in the pathogenesis of multiple myeloma, particularly in patients with the t(4;14) translocation. Developed by K36 Therapeutics, KTX-1029 has demonstrated strong biochemical potency against full-length NSD2 and high selectivity over other histone methyltransferases. Preclinical studies show that it effectively reduces H3K36me2 levels and inhibits colony formation in t(4;14) multiple myeloma cell lines. In vivo efficacy has been observed both as a single agent and in combination with proteasome inhibitors such as bortezomib and carfilzomib, including activity in proteasome inhibitor-sensitive and -resistant models. The drug is currently at the preclinical development stage for multiple myeloma[1][2][4][5][6].